Ardelyx ARDX

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.02 (-0.38%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Ardelyx (ARDX)
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $5.3

  • Market Cap

    $1.24 Billion

  • Price-Earnings Ratio

    -31.18

  • Total Outstanding Shares

    233.98 Million Shares

  • Total Employees

    267

  • Dividend

    No dividend

  • IPO Date

    June 19, 2014

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    34175 ardenwood blvd., Fremont, CA, 94555

  • Homepage

    https://www.ardelyx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Investing Activities$-18.32 Million
Net Cash Flow From Financing Activities, Continuing$106.59 Million
Net Cash Flow From Investing Activities, Continuing$-18.32 Million
Net Cash Flow From Operating Activities$-44.81 Million
Net Cash Flow From Financing Activities$106.59 Million
Net Cash Flow, Continuing$43.46 Million

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Revenues$333.62 Million
Operating Expenses$311.01 Million
Operating Income/Loss$-27.95 Million
Selling, General, and Administrative Expenses$258.69 Million
Net Income/Loss Attributable To Noncontrolling Interest$0
Cost Of Revenue$50.56 Million

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss Attributable To Parent$-39.30 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$-39.30 Million
Comprehensive Income/Loss$-39.30 Million

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Current Assets$356.45 Million
Liabilities And Equity$435.75 Million
Current Liabilities$77.83 Million
Wages$14.94 Million
Other Non-current Assets$77.81 Million
Other Current Assets$265.27 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ARDX from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.